Psoriatic Arthritis News Archive
Cardiovascular risk should be carefully evaluated in patients with psoriatic arthritis.
Researchers compared definitions of remission and low disease activity in patients with psoriatic arthritis.
Investigators examined the performance of various definitions in patients with PsA and psoriasis.
Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.
Data show that filgotinib is effective for the treatment of active psoriatic arthritis.
Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.
Investigators assessed radiographic progression in patients with psoriatic arthritis following transition from conventional synthetic disease-modifying rheumatic drugs to anti-tumor necrosis factor-α therapy.
Investigators sought to determine the validity of using a simplified scoring tool that assesses 28 joint counts compared with the original 66/68 joint counts in patients with psoriatic arthritis.
Investigators explore the impact of pregnancy on PsA disease activity, as well as the effect of biologic therapy on PsA disease activity during and following pregnancy.
Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.
Results from the RAPID-PsA study showed that patients with PsA who are treated with certolizumab pegol sustained improvements over the course of 4 years when it is taken as a monotherapy or concomitant with DMARDs.
Researchers quantified the incidence of orthopedic procedures in patients with psoriatic arthritis.
Data show that psoriatic arthritis acts as a strong enhancer of age-related catabolic bone damage.
Rheumatologist-assessed inflammatory back pain (IBP) or the criteria for IBP developed for ankylosing spondylitis might not perform well when determining axial involvement in psoriatic arthritis.
Disease activity was altogether low and stable from preconception to 1 year postpartum among pregnant women with psoriatic arthritis.
The safety profile of ixekizumab in the treatment of psoriatic arthritis is similar to the safety profile observed with ixekizumab for the treatment of plaque psoriasis.
Sustained minimal disease activity should be maintained for a prolonged period in order to prevent progression of carotid atherosclerosis and arterial stiffness in patients with PsA.
A final reliable ultrasound score and definition of enthesitis in SpA and PsA were produced by the OMERACT group.
Treatment with secukinumab over 24 weeks led to a decrease of synovial inflammation and no progression of catabolic and anabolic bone changes in patients with PsA.
ABT-122 demonstrated acceptable tolerability and maintenance of efficacy at 36 weeks in patients with RA or PsA receiving background methotrexate.
Minimal disease activity provided a stable and valid assessment of clinical status over the course of 24 months in patients with psoriatic arthritis.
Sonographic enthesitis scoring instruments have been developed for spondyloarthritis, but only a few have been validated in psoriatic arthritis.
Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.
Widespread nonarthritic pain is linked to worse patient-reported and composite psoriatic arthritis activity measures.
Researchers analyzed the characteristics of patients with psoriatic arthritis with and without axial involvement.
Health-related quality of life was diminished in psoriatic arthritis at time of diagnosis compared with the general population.
Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.
High-intensity interval training showed no clear effects on disease activity markers in patients with psoriatic arthritis.
Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.
Male gender was associated with better biologic treatment effectiveness in psoriatic arthritis.
Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.
The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.
The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.
Investigators sought to determine the rate of conversion of Quantiferon-TB Gold screening test in patients taking anti-TNF therapy.
Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.
The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.
Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.
The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.
Dual inhibition of IL-17A and IL-17F with bimekizumab suppresses joint inflammation in patients with psoriatic arthritis.
The accessory pulleys linked to the flexor tendons are thicker in patients with psoriatic arthritis.
Initial response to psoriatic arthritis therapy has a predictive value of long-term outcomes as early as 3 months after treatment initiation.
Results from the FUTURE 2 study show that patients with PsA who were treated with secukinumab achieved early and sustained minimal disease activity over 2 years of therapy.
Results from the phase 3 SPIRIT-P1 study show that treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile.
A cohort study was conducted to determine the long-term outcomes especially of cardiovascular and kidney diseases in patients with psoriatic arthritis with comorbid hyperuricemia.
There is a higher risk for liver disease in patients with inflammatory disorders.
The FDA has approved tofacitinib and tofacitinib extended release to treat active psoriatic arthritis.
Investigators compared composite scores defining low disease activity state or remission in an existing real-life data set of patients with PsA.
Disease severity and activity in psoriatic arthritis may predict coronary plaque burden better than traditional risk factors.
Cardiovascular risk assessment tools in patients with PsA have been shown to underestimate the risk for carotid subclinical atherosclerosis.
The FDA has approved ixekizumab for the treatment of adults with psoriatic arthritis.
Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.
TNFi persistence and factors influencing persistence were investigated in patients who were treated with TNFi therapy for the first time.
Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.
The risk for symptom flares is substantial after TNFi discontinuation in patients with psoriatic arthritis who had achieved remission/low disease activity.
Tofacitinib may be effective in reducing psoriatic arthritis activity in patients with inadequate response to TNF inhibitors.
Although remission is the ultimate goal among patients with psoriatic arthritis and their physicians, many unanswered questions on what precisely we should aim to achieve still remain.
Simponi Aria has been approved by the FDA for treating PsA or ankylosing spondylitis.
Psoriatic arthritis treatment with intravenous golimumab leads to improved outcomes.
Inhibitors of interkeukins 6, 12, 23 and 17A were shown to be effective and generally well-tolerated agents for the treatment of psoriatic arthritis.
Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.
Overall improvements in rates of minimal disease activity are achieved in patients with PsA when they are treated with anti-tumor necrosis factor agents
Smoking is associated with the risk of psoriasis.
A noninvasive test can be used to help monitor for risk of worsening fibrosis in psoriasis patients who have elevated hepatic steatosis.
The association between sonographic enthesitis and severity of radiographic features of peripheral and axial joint damage in psoriatic arthritis was examined in a cross-sectional study.
Less than 40% of psoriatic arthritis patients were treated with a bDMARD.
Dalazatide treatment can improve skin lesions for patients with plaque psoriasis.
The first US study to examine an interchangeability designation for an adalimumab biosimilar candidate is investigating interchangeability between BI 695501 and Humira 40mg/0.8mL.
The ability of Power Doppler Ultrasound to predict short-term psoriatic arthritis disease flare was investigated in a new study.
ABP 501 is safe to use for treating moderate to severe plaque psoriasis.
The researchers noted that the small changes in lipid profile do not account for the cardiovascular benefits seen in patients taking etanercept.
Psoriasis patients have high rates hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
There was improvement in nail psoriasis severity at 16 weeks compared with placebo that was maintained through 52 weeks.
Repeated serum amyloid A measurements could act as an additional marker for monitoring disease activity over time in patients with psoriatic arthritis.
Ixekizumab was found to benefit patients with psoriatic arthritis showing poor response to conventional treatment when administered over a 2- or 4-week period.
Patients with severe psoriasis and those with mild psoriasis and concomitant psoriatic arthritis have an increased risk of uveitis.
Psoriatic arthritis, patient weight, registration country and more influence first-line biologic treatment selection for patients with psoriasis.
Women were found to have a lower median of scores in the Psoriasis Area and Severity Index than men.
Prospective cohort study of patients with psoriasis who were assessed annually to examine for development of clinical psoriatic arthritis.
Findings come from 2 trials; one compared secukinumab with placebo, whereas the other compared secukinumab with placebo and etanercept.
Study evaluated clinical data to determine a possible role of major depressive disorders in the progression of inflammatory disease.
Most patients with psoriasis who were withdrawn from ixekizumab therapy experienced disease relapse.
Researchers find that higher levels of disease activity predict the development of diabetes mellitus in patients with psoriatic arthritis.
Emotional well-being negatively impacted among parents with affected children.
Obese patients with psoriasis experience quality-of-life improvement after losing significant amounts of weight.
Highest risk for reduction in HRQoL for hidradenitis suppurativa, blistering conditions, psoriasis
Researchers found that lower education, higher disease visibility, severity, duration, and Type D personality were tied to stigmatization.
Results were announced from a phase 3 trials assessing safety and efficacy of tofacitinib citrate for active psoriatic arthritis
Data from a Phase 2b clinical trial supported the safety and efficacy of clazakizumab in active psoriatic arthritis with or without methotrexate.
In this nested case-control study, after controlling for age, sex, diagnosis, ASA class, race, preoperative WOMAC pain and function scores, and smoking history, neither PsA and PsC were found to be risk factors for worse THA outcomes.
Results from the GO-REVEAL trial indicate that golimumab treatment is associated with long-term improvement in psoriatic arthritis.
Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic Immune Disorders
Normal skin tissue morphology restored in psoriatic mice implanted with microencapsulated cytokine converter transgenic designer cells.
A targeted treatment approach may provide benefit for patients with psoriatic arthritis.
Both early intervention and targeted treatment more effectively treat psoriatic arthritis than standard care, according to data published in The Lancet.
Recent research has identified new targeted therapies for psoriasis and psoriatic arthritis.
Rheumatology Advisor Articles
- Synovial Thickening on Ultrasonography May Predict Arthritis Development
- Lutikizumab May Not Improve Outcomes in Erosive Hand Osteoarthritis
- Tender Joint Count May Not Reflect Inflammation Activity in Rheumatoid Arthritis
- Urine Immunoassay Identifies Novel Lupus Nephritis Biomarkers
- Smoking Linked to Increased Disease Activity in Rheumatoid Arthritis
- Using Telemedicine in Rheumatology: Outcomes, Costs, and Patient Satisfaction
- New Appointment Algorithm Helps Clinicians Manage Time Better
- Urine Immunoassay Identifies Novel Lupus Nephritis Biomarkers
- Ultrasound: A Sensitive Imaging Tool for Evaluating Suspected CPPD in Hip Joints
- Managing Bisphosphonate Drug Holidays in Patients With Osteoporosis
- No Clinically Meaningful Safety Differences Between Sarilumab, Tocilizumab in RA
- Biologic Therapies in JIA: International Registry Data Combined
- Risk Factors Associated With Chronic Opioid Use in Musculoskeletal Pain
- DHS, HHS Proposal Set to Upend Health Care for Non-Citizen Children
- Protecting Your Practice From Data Breaches: An Expert Interview